On December 15th, the interface news broke outThe State Food and Drug Administration has decided to suspend the import, sale and use of the well-known drug levetiracetam concentrated solution for injection, and there is a situation where the sale and use of levetiracetam continue to be sold and used. As a result, the People's Hospital of Xinjiang Uygur Autonomous Region also received a medical insurance audit and rectification opinion issued by the local medical insurance ** regulatory affairs center.
On August 22, 2022, UCB was punished by the State Food and Drug Administration for "incorrect labeling of the expiration date on the package", suspending the import, sale and use of this variety in China, and UCB also launched a national recall of this drug.
However, judging from the content of the interface news report, the hospital believes that it is responsible for the commercial promotion of the drug in XinjiangSinopharm Xinjiang Xinte Pharmaceutical does not appear to have initiated the deactivation and recall work in a timely mannerAs a result, the People's Hospital of Xinjiang Uygur Autonomous Region was still using this drug after August 22, 2022, and it was not discovered by the department until it applied for medical insurance reimbursement.
The People's Hospital of Xinjiang Uygur Autonomous Region has been suspended by the State Food and Drug Administration for illegal use of drugs, and has been required to rectify by the medical insurance department. Based on this, the hospital believes that the medical insurance funds involved in the illegal use should be borne by Sinopharm Xinjiang Xinte Pharmaceutical.
At present, none of the parties involved in this incident have a clear solution.
Written by |Liang Jian.
Edit |Jiang Yun Jia Ting.
Operations |Valley.